Otsuka gets Japanese rights to Takara's TCR, CAR therapies

Takara Bio Inc. (Tokyo:4974) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive co-development and Japanese commercialization rights to cancer candidates TBI-1301, a cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-targeted short interfering T cell receptor therapy, and TBI-1501, a CD19-targeted chimeric antigen receptor candidate.

Takara is eligible for ¥6.3 billion ($59 million) in an upfront payment and milestones, plus royalties...